Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.
Bruker Applied MS will showcase two significant innovations: the integration of RECIPE's ClinMass ® and ClinDART ® assay kits with Bruker's EVOQ ® DART-TQ⁺ system for TDM and DoA applications, and the launch of the new timsMetabo™ platform for advanced small molecule analysis. These developments support Bruker's goal of delivering practical, high-performance solutions for routine analytical challenges.
Bruker's recent majority investment in RECIPE, a renowned manufacturer of diagnostic assays for small molecule analysis used with triple quadrupole mass spectrometers, marks an important step in expanding its capabilities in TDM and DoA analysis. Since the acquisition, Bruker and RECIPE have collaborated to verify the IVDR certified ClinMASS ® kits for use on the EVOQ DART-TQ⁺ system, initially targeting high-priority compound classes. They are not US-FDA approved, but single compounds as controls and calibrators may be a basis in LDT approaches. In parallel, the companies are preparing the launch of RECIPE's ClinDART ® kits, which are designed as high-throughput, chromatography-free assays for the EVOQ DART-TQ⁺ system. These kits enable rapid, cost-efficient analysis with highly reduced solvent consumption, ease of use and increased lab productivity. All ClinDART ® protocols are currently designated for Research Use Only (RUO).
Meanwhile, the newly introduced timsMetabo™ platform represents a leap forward in small molecule analysis. Built on Bruker's proprietary trapped ion mobility spectrometry (TIMS) and enhanced with Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP), timsMetabo™ delivers high sensitivity and selectivity for PFAS detection. In early studies, timsMetabo™ identified 40% more low-mass molecules in water samples compared to previous-generation systems. This innovation supports both regulatory compliance and proactive environmental monitoring, with promising applications in toxicology and forensic science.
'The integration of RECIPE's assay expertise with Bruker's DART triple quad instrumentation is a significant advancement for therapeutic drug monitoring,' said Dr. Gernot Wolfram, Managing Director of RECIPE. 'It represents a promising concept with the potential to enable laboratories to adopt high-throughput, chromatography-free workflows that are efficient, robust, and more sustainable. These could dramatically enhance overall lab productivity and make mass spectrometry more accessible and impactful in routine clinical settings.'
'ASMS 2025 marks an important milestone for Bruker Applied MS,' said Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry. 'With the launch of timsMetabo™ and the strategic integration of RECIPE, we are not only expanding our technology portfolio but also redefining what's possible in applied markets. These innovations reflect our commitment to solving real-world analytical challenges in TDM and environmental analysis.'
Looking ahead, Bruker Applied MS will continue to develop solutions for PFAS, forensic toxicology, and therapeutic drug monitoring. The timsMetabo™ platform is expected to support future applications involving low-mass drug metabolites and emerging contaminants, while RECIPE's assay pipeline will further enhance Bruker's applied market offerings.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
an hour ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
an hour ago
- Yahoo
Why Digital Turbine Stock Plummeted Today
Digital Turbine stock saw a massive post-earnings rally on Tuesday, but its share price slipped as the week progressed. Investors took profits on the stock today, and geopolitical risk factors also worked to push its share price lower. Digital Turbine is guiding for strong adjusted EBITDA growth this year, but geopolitical dynamics could create valuation volatility. 10 stocks we like better than Digital Turbine › Digital Turbine (NASDAQ: APPS) stock saw a round of substantial sell-offs Friday. The adtech specialist's share price closed out the daily session down 14.6% amid a 0.3% decline for the S&P 500 index and a 0.6% decline for the Nasdaq Composite index. Following an explosive post-earnings rally for the stock earlier this week, investors sold shares and moved to take profits. In addition to profit-taking action, Digital Turbine stock moved lower due to new restrictions on technology exports and fears that the conflict between Israel and Iran could continue to escalate. Digital Turbine stock had actually been up as much as 1.8% in today's trading, but action on the stock turned bearish as investors reacted to risk factors and took profits on gains posted earlier in the week. The company's share price skyrocketed in Tuesday's trading after it posted better-than-expected quarterly results and forward guidance, but its share price has moved lower in subsequent trading. In addition to profit-taking activities, Digital Turbine stock was pressured by geopolitical dynamics today. The Wall Street Journal published a report today stating that the Trump administration wants to further strengthen export restrictions and prevent companies including Samsung, Taiwan Semiconductor Manufacturing, and SK Hynix from shipping chipmaking technologies to their factories in China. Adding another bearish catalyst, investors moved out of stocks due to the possibility that military strikes between Israel and Iran will intensify and that the U.S. could enter the conflict on behalf of Israel. For the current fiscal year, Digital Turbine is guiding for revenue between $515 million and $525 million -- good for annual growth of roughly 6% at the midpoint of the target range. Meanwhile, non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) are projected to be between $85 million and $90 million -- representing growth of 21% at the midpoint of the guidance range. Digital Turbine's performance outlook became significantly stronger following its quarterly release earlier this week, but there are factors that could cause continued volatility for the stock. The company does most of its business in China, and rising geopolitical tensions present substantial risk factors even though it's not a hardware company. Before you buy stock in Digital Turbine, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Digital Turbine wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. Why Digital Turbine Stock Plummeted Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
